Alcresta Therapeutics

-5%

est. 2Y upside i

HealthcareSeries D+

Rank

#2418

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Data confidence is low due to missing revenue and valuation figures.

Last updated: July 19, 2026

Bull (20%)+100%

Revenue growth accelerates from FDA approvals for new indications, driving a 2x exit via sale or IPO, benefiting from proprietary technology.

Base (55%)0%

Revenue grows at historical 33% but multiple compresses as growth normalizes; valuation stagnates near current implied value.

Bear (25%)-100%

Exit value falls below $95.9M total funding; common stock worthless after preference liquidation preference.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

10000%

Total funding of $95.9M vs. entry valuation proxy of $95.9M implies 100% preference overhang; common stock recovery unlikely in a downside exit.

Dilution Risk

high

Additional capital likely needed before exit given high capital intensity and no profitability; new rounds would dilute common equity significantly.

Secondary Liquidity

none

PE ownership typically restricts secondary sales; no active secondary market observed.

Other — 5 roles

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Alcresta Therapeutics's data — designed to show you've done your homework.

1
“How does the company plan to expand RELiZORB adoption beyond cystic fibrosis into broader GI disorders?”
2
“What is the current revenue run rate and how does subscription revenue trend with patient growth?”
3
“Given PE ownership, what is the expected liquidity pathway for employees (e.g., secondary sales, IPO timeline)?”

Our model estimates -5% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.